Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
Not yet recruiting · NCT04366115 · Registry updated 2025-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, influenza, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Not yet recruiting | Phase 1 | 2025-10-02 | NCT04366115 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AVM Biotechnology Inc | 2 |
| Medpace, Inc. | 17 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||